SUSTAIN-6 was a cardiovascular outcomes trial that enrolled over 3,000 patients to evaluate semaglutide’s effects on major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk. The trial demonstrated that once-weekly subcutaneous semaglutide reduced the composite outcome of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26 percent compared to placebo. This reduction was consistent across multiple subgroups and represented a significant advancement in demonstrating class-level cardiovascular benefit for GLP-1 receptor agonists beyond glucose lowering alone.
Tirzepatide, as a dual GIP and GLP-1 receptor agonist, represents a pharmacologically distinct mechanism compared to semaglutide’s selective GLP-1 agonism. While tirzepatide has demonstrated superior glycemic control and weight reduction in comparative trials with semaglutide, the cardiovascular outcomes data for tirzepatide comes from post-hoc analyses and shorter-term safety monitoring rather than dedicated large-scale cardiovascular outcomes trials comparable to SUSTAIN-6. Current evidence suggests both agents provide cardiovascular benefit, though the magnitude and clinical profile may differ based on their distinct receptor pharmacology.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →For prescribers, the established cardiovascular benefit demonstrated in SUSTAIN-6 provides robust evidence supporting semaglutide’s use in patients with type 2 diabetes who have concomitant cardiovascular disease or significant cardiovascular risk factors. The choice between semaglutide and tirzepatide should consider individual patient factors including glycemic targets, weight loss goals, tolerability profile, and the strength of available cardiovascular outcomes evidence when making treatment decisions.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is the difference between semaglutide and tirzepatide?
- Do these medications help protect the heart?
- What was the SUSTAIN-6 trial and why does it matter?
- Am I a candidate for GLP-1 therapy if I don’t have diabetes?
- How quickly will I see heart benefits from these medications?
- Does tirzepatide work better than semaglutide for the heart?
- What are the common side effects I should expect?
- Can I stop taking these medications once I reach my goals?
- Are these medications safe for people with a history of thyroid cancer?
- How often do I need to take these medications?
- Read next
FAQ
What is the difference between semaglutide and tirzepatide?
Semaglutide works by mimicking one hormone called GLP-1, while tirzepatide mimics two hormones called GLP-1 and GIP. Both medications help control blood sugar and weight, but tirzepatide affects the body through two different pathways, which may produce stronger effects in some patients.
Do these medications help protect the heart?
Yes, both semaglutide and tirzepatide have been shown in clinical trials to reduce the risk of heart attacks and strokes in patients with type 2 diabetes and cardiovascular disease. These benefits appear to go beyond just lowering blood sugar.
What was the SUSTAIN-6 trial and why does it matter?
SUSTAIN-6 was a major clinical study that enrolled over 3,000 patients to test whether semaglutide could prevent heart problems in people with diabetes. This trial provided strong evidence that the medication reduces serious cardiovascular events like heart attacks and strokes.
Am I a candidate for GLP-1 therapy if I don’t have diabetes?
GLP-1 medications are approved for type 2 diabetes and weight management, but your doctor may consider them for other reasons based on your personal health situation, including family history of heart disease or existing cardiovascular conditions. You should discuss your individual risk factors with your physician.
How quickly will I see heart benefits from these medications?
The cardiovascular benefits shown in major trials typically take months to years to fully develop, though weight loss and blood sugar improvements may happen within weeks. The heart protection builds over time as your metabolism and cardiovascular risk factors improve.
Does tirzepatide work better than semaglutide for the heart?
Both medications have shown cardiovascular benefits in clinical studies, though direct comparison data is still emerging. Your doctor can help determine which medication is better suited to your specific health needs based on your medical history and risk factors.
What are the common side effects I should expect?
The most common side effects are nausea, vomiting, and constipation, which typically occur when starting the medication or increasing the dose. These effects often improve over time as your body adjusts to the medication.
Can I stop taking these medications once I reach my goals?
These medications work best when taken long-term because benefits like weight loss and cardiovascular protection tend to decrease when you stop taking them. Stopping should always be done under your doctor’s supervision based on your individual situation.
Are these medications safe for people with a history of thyroid cancer?
Semaglutide and tirzepatide are not recommended for patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. You must inform your doctor about any thyroid cancer history before starting these medications.
How often do I need to take these medications?
Both semaglutide and tirzepatide are injected once per week under the skin, making them convenient compared to daily pills. Your doctor will show you how to give yourself the injection, and many patients find the weekly schedule easier to remember than daily medications.
